Lataa...
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response
Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-v...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814164/ https://ncbi.nlm.nih.gov/pubmed/29464024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23725 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|